Venture Visionary Partners LLC Sells 2,283 Shares of The Clorox Company $CLX

Key Points

• Venture Visionary Partners LLC has decreased its holdings in The Clorox Company by 51.1%, selling 2,283 shares and now owning 2,184 shares worth approximately $322,000.
• Analyst ratings for Clorox have been mixed, with one "Buy," eight "Hold," and three "Sell" ratings, while the price targets range from $135.00 to $167.00.
• Clorox announced a quarterly dividend increase to $1.24 per share, reflecting an annual yield of 4.1%, and has set its FY 2026 guidance at $5.95 to $6.30 EPS.

Venture Visionary Partners LLC lessened its holdings in The Clorox Company (NYSE:CLX - Free Report) by 51.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,184 shares of the company's stock after selling 2,283 shares during the period. Venture Visionary Partners LLC's holdings in Clorox were worth $322,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Wood Tarver Financial Group LLC acquired a new stake in shares of Clorox in the 4th quarter valued at $31,000. GW&K Investment Management LLC raised its holdings in Clorox by 239.1% in the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company's stock worth $43,000 after acquiring an additional 208 shares during the period. Roble Belko & Company Inc raised its holdings in Clorox by 140.7% in the 1st quarter. Roble Belko & Company Inc now owns 361 shares of the company's stock worth $53,000 after acquiring an additional 211 shares during the period. IMA Advisory Services Inc. bought a new position in Clorox in the 1st quarter worth $58,000. Finally, Menard Financial Group LLC bought a new position in Clorox in the 4th quarter worth $63,000. Institutional investors and hedge funds own 78.53% of the company's stock.

Clorox Price Performance

NYSE CLX traded down $0.82 on Monday, reaching $119.49. The company's stock had a trading volume of 1,814,588 shares, compared to its average volume of 1,640,658. The firm has a market cap of $14.61 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 0.96 and a beta of 0.49. The business has a 50-day moving average price of $124.25 and a 200 day moving average price of $135.22. The Clorox Company has a 52 week low of $117.35 and a 52 week high of $171.37. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, beating analysts' consensus estimates of $2.24 by $0.63. The business had revenue of $1.99 billion for the quarter, compared to analysts' expectations of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The firm's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Sell-side analysts expect that The Clorox Company will post 7.15 EPS for the current year.

Clorox Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 29th. Investors of record on Wednesday, August 13th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Wednesday, August 13th. This is an increase from Clorox's previous quarterly dividend of $1.22. This represents a $4.96 dividend on an annualized basis and a yield of 4.2%. Clorox's payout ratio is presently 76.07%.

Wall Street Analyst Weigh In

CLX has been the topic of several recent analyst reports. Barclays dropped their target price on shares of Clorox from $129.00 to $119.00 and set an "underweight" rating on the stock in a report on Tuesday, July 15th. Jefferies Financial Group dropped their target price on shares of Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. JPMorgan Chase & Co. dropped their price objective on shares of Clorox from $144.00 to $140.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. UBS Group dropped their price objective on shares of Clorox from $150.00 to $134.00 and set a "neutral" rating on the stock in a report on Thursday, July 17th. Finally, Morgan Stanley dropped their price objective on shares of Clorox from $150.00 to $137.00 and set an "equal weight" rating on the stock in a report on Friday, August 1st. One research analyst has rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Reduce" and an average price target of $143.36.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.